1017-42-1Relevant articles and documents
A 2-pyridone modified zinc phthalocyanine with three-in-one multiple functions for photodynamic therapy
Li, Yanqing,Wang, Chongchong,Wei, Shaohua,Zhou, Lin
, p. 3127 - 3130 (2021)
A 2-pyridone modified zinc phthalocyanine (denoted ZnPc-PYR) achieves a one stone for three birds outcome in the photodynamic therapy (PDT) treatment of cancer. ZnPc-PYR can be excited by both 665 and 808 nm light to treat superficial and deep tumors, store and slowly release singlet oxygen (1O2) to improve its utilization and downregulate the HIF-1 (hypoxia-inducible factor 1) expression level to enhance the tumor cell's sensitivity to PDT treatment under hypoxic conditions.
Pyridone modified zinc phthalocyanine as well as preparation method and application thereof
-
Paragraph 0043; 0046-0047; 0050-0053, (2021/05/19)
The invention discloses pyridone-modified zinc phthalocyanine and a preparation method and application thereof. The pyridone-modified zinc phthalocyanine has the structural formula shown in the specification, novel zinc phthalocyanine is easy and convenie
THERAPEUTIC INHIBITORY COMPOUNDS
-
Page/Page column 45, (2015/07/16)
The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.